Lupin debuts generics of two Watson drugs, NOR-QD and Fortamet, in USA

16 October 2011

Indian drugmaker Lupin (500257. BY) last week revealed that it had launched generic versions in the USA of two product originated by USA-based Watson Pharmaceuticals (NYSE: WPI), one an authorized version and the other on an at risk basis.

First, US subsidiary Lupin Pharmaceuticals has debuted Femcon Fe (norethindrone and ethinyl estradiol tablets, chewable and ferrous fumarate tablets) 0.4mg/35mcg is a low-dose chewable birth control tablet that can also be swallowed immediately followed by a full glass (8 oz.) of liquid. This authorized generic product will be manufactured under the brand product’s new drug application or NDA at the same facility where it is currently produced.

The drug is a new formulation of Watson’s NOR-QD and was approved by the US Food and Drug Administration on September 20. Combined annual sales for NOR-QD and its generic equivalents were around $52 million for the 12 months ended June 2011 based on IMS Health sales data.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK